trial · primary record
Siplizumab
Renal Transplant Failure and Rejection
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2028-03-28 |
| Primary endpoint | Assessment of the safety of 2 dose levels of siplizumab versus rATG. |
| Registry ID | NCT07508787 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:48.287Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07508787
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.